204 related articles for article (PubMed ID: 22592665)
21. Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria.
Abe M; Okada K; Maruyama N; Matsumoto S; Maruyama T; Fujita T; Matsumoto K; Soma M
Hypertens Res; 2011 Feb; 34(2):268-73. PubMed ID: 21124330
[TBL] [Abstract][Full Text] [Related]
22. Effect of aliskiren in chronic kidney disease patients with refractory hypertension undergoing hemodialysis: a randomized controlled multicenter study.
Kuriyama S; Yokoyama K; Hara Y; Sugano N; Yokoo T; Hosoya T
Clin Exp Nephrol; 2014 Oct; 18(5):821-30. PubMed ID: 24253615
[TBL] [Abstract][Full Text] [Related]
23. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
Kuriyama S; Tomonari H; Tokudome G; Horiguchi M; Hayashi H; Kobayashi H; Ishikawa M; Hosoya T
Hypertens Res; 2002 Nov; 25(6):849-55. PubMed ID: 12484508
[TBL] [Abstract][Full Text] [Related]
24. S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial.
Jo SH; Park SJ; Kim EJ; Kim SJ; Cho HJ; Song JM; Shin J; Park JJ; Shin JH; Han KR; Choi DJ
Trials; 2018 Jun; 19(1):324. PubMed ID: 29925421
[TBL] [Abstract][Full Text] [Related]
25. Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy.
Persson F; Lewis JB; Lewis EJ; Rossing P; Hollenberg NK; Hans-Henrik P
J Renin Angiotensin Aldosterone Syst; 2012 Mar; 13(1):118-21. PubMed ID: 21824990
[TBL] [Abstract][Full Text] [Related]
26. An observational, prospective, open-label, multicentre evaluation of aliskiren in treated, uncontrolled patients: a real-life, long-term, follow-up, clinical practice in Italy.
Tocci G; Aimo G; Caputo D; De Matteis C; Di Napoli T; Granatelli A; Lentini P; Magagna A; Matarrese AA; Perona D; Villa G; Volpe M;
High Blood Press Cardiovasc Prev; 2012 Jun; 19(2):73-83. PubMed ID: 22867093
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of two fixed-dose combinations of S-amlodipine and telmisartan (CKD-828) versus S-amlodipine monotherapy in patients with hypertension inadequately controlled using S-amlodipine monotherapy: an 8-week, multicenter, randomized, double-blind, Phase III clinical study.
Ihm SH; Jeon HK; Cha TJ; Hong TJ; Kim SH; Lee NH; Yoon JH; Yoon N; Hwang KK; Jo SH; Youn HJ
Drug Des Devel Ther; 2016; 10():3817-3826. PubMed ID: 27920497
[TBL] [Abstract][Full Text] [Related]
28. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.
Nakamura T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H; Inoue T; Node K
Am J Med Sci; 2007 Jun; 333(6):321-6. PubMed ID: 17570983
[TBL] [Abstract][Full Text] [Related]
29. Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy.
Persson F; Lewis JB; Lewis EJ; Rossing P; Hollenberg NK; Parving HH;
Diabetes Care; 2010 Nov; 33(11):2304-9. PubMed ID: 20693353
[TBL] [Abstract][Full Text] [Related]
30. Greater reductions in plasma aldosterone with aliskiren in hypertensive patients with higher soluble (Pro)renin receptor level.
Bokuda K; Morimoto S; Seki Y; Yatabe M; Watanabe D; Yatabe J; Ando T; Shimizu S; Itoh H; Ichihara A
Hypertens Res; 2018 Jun; 41(6):435-443. PubMed ID: 29618841
[TBL] [Abstract][Full Text] [Related]
31. Safety of enhanced renin-angiotensin-aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease.
Lizakowski S; Tylicki L; Rutkowski P; Renke M; Sulikowska B; Heleniak Z; Donderski R; Bednarski R; Przybylska M; Manitius J; Rutkowski B
Pol Arch Med Wewn; 2013; 123(5):221-7. PubMed ID: 23615633
[TBL] [Abstract][Full Text] [Related]
32. Aliskiren reduces morning blood pressure in hypertensive patients with diabetic nephropathy on hemodialysis.
Takenaka T; Okayama M; Kojima E; Nodaira Y; Arai J; Uchida K; Kikuta T; Sueyoshi K; Hoshi H; Watanabe Y; Takane H; Suzuki H
Clin Exp Hypertens; 2013; 35(4):244-9. PubMed ID: 23534458
[TBL] [Abstract][Full Text] [Related]
33. Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.
Nakamura T; Fujiwara N; Sato E; Ueda Y; Sugaya T; Koide H
Kidney Blood Press Res; 2010; 33(3):213-20. PubMed ID: 20588058
[TBL] [Abstract][Full Text] [Related]
34. Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.
Aritomi S; Niinuma K; Ogawa T; Konda T; Nitta K
Clin Exp Nephrol; 2013 Feb; 17(1):41-50. PubMed ID: 23011292
[TBL] [Abstract][Full Text] [Related]
35. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
Jordan J; Engeli S; Boye SW; Le Breton S; Keefe DL
Hypertension; 2007 May; 49(5):1047-55. PubMed ID: 17353513
[TBL] [Abstract][Full Text] [Related]
36. Antihypertensive efficacy and tolerability of aliskiren/amlodipine single- pill combinations in patients with an inadequate response to aliskiren monotherapy.
Glorioso N; Thomas M; Troffa C; Argiolas G; Patel S; Baek I; Zhang J
Curr Vasc Pharmacol; 2012 Nov; 10(6):748-55. PubMed ID: 22303910
[TBL] [Abstract][Full Text] [Related]
37. Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease.
Moriyama T; Tsuruta Y; Kojima C; Itabashi M; Sugiura H; Takei T; Ogawa T; Uchida K; Tsuchiya K; Nitta K
Int Urol Nephrol; 2012 Jun; 44(3):841-5. PubMed ID: 21626132
[TBL] [Abstract][Full Text] [Related]
38. Effects of aliskiren on blood pressure and humoral factors in hypertensive hemodialysis patients previously on angiotensin II receptor antagonists.
Ito T; Ishikawa E; Fujimoto N; Okubo S; Ito G; Ichikawa T; Nomura S; Ito M
Clin Exp Hypertens; 2014; 36(7):497-502. PubMed ID: 24433061
[TBL] [Abstract][Full Text] [Related]
39. Renoprotection by Direct Renin Inhibition: A Systematic Review and Meta- Analysis.
Louvis N; Coulson J
Curr Vasc Pharmacol; 2018 Jan; 16(2):157-167. PubMed ID: 28464775
[TBL] [Abstract][Full Text] [Related]
40. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
